It is now widely established that cancer and aging are intrinsically linked. People over the age of 65 make up 60 percent of new cancer diagnoses and 70 percent of cancer deaths. As advances in medicine and healthcare maximize human life expectancy and the elderly population continues to grow, cancer rates are predicted to increase accordingly.
CD BioSciences offers preclinical contract research services dedicated to advancing the field of aging-related cancer research and drug development. With years of experience in the industry, our team of highly proficient biological scientists and experts is committed to providing comprehensive and reliable services to our clients.
At CD BioSciences, we offer a wide range of research and development (R&D) services tailored to different types of aging-related cancers. By focusing on specific cancer types, we can provide specialized insights and solutions to address the unique challenges posed by each disease.
At CD BioSciences, we employ technologies and methodologies to comprehensively analyze cancer biology in the context of aging-related cancers.
Unraveling the pathogenesis of aging-related cancers is essential for identifying key molecular pathways and cellular processes involved in tumor development. CD BioSciences offers comprehensive analysis services aimed at elucidating the pathogenesis of aging-related cancers, enabling the discovery of novel therapeutic targets.
CD BioSciences offers comprehensive biomarker identification services for aging-related cancers, allowing for the discovery and validation of novel biomarkers with clinical relevance. Using genomic sequencing, mass spectrometry, and immunoassays, we identify genomic and proteomic alterations that hold diagnostic or prognostic value for aging-related cancers. Our services aim to uncover specific biomarkers associated with aging-related cancer subtypes, treatment response, and disease progression.
CD BioSciences provides disease model customization services to facilitate robust and reliable preclinical research. We offer in vitro and in vivo model customization services, such as the patient-derived xenograft (PDX) model, cell-based models, and animal models, to help clients explore the molecular mechanisms underlying tumor development, progression, and response to interventions. Our disease models play a crucial role in evaluating different pharmacological interventions.
CD BioSciences offers comprehensive drug discovery and development services specifically tailored for aging-related cancers. Our services encompass various stages of the drug development process, from target identification and validation to preclinical studies. We conduct rigorous in vitro and in vivo studies to assess the efficacy of potential drug candidates against aging-related cancers. We perform comprehensive pharmacokinetic and toxicity studies to assess the safety and tolerability of potential drug candidates. These studies provide valuable data on compound absorption, distribution, metabolism, excretion (ADME) as well as potential adverse effects.
CD BioSciences is dedicated to advancing aging-related cancer research and drug development through our comprehensive range of services. Our extensive expertise and commitment to scientific excellence make us an ideal partner for accelerating the development of novel therapies for aging-related cancers. If you are interested in our services, please feel free to contact us or make an online inquiry.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.